News

The results from a Phase III trial showed with weekly subcutaneous injections for 72 weeks, Teribone helps in decreasing the risk of developing new vertebral fracture by 78.6%

The results from a Phase II Saphire study investigating resminostat as a third-line treatment in relapsed/refractory HL patients, showed a 33.3% overall response rate and 54.5% of patients

The new EHR enables the US healthcare practitioners to document clinical notes, schedule office visits, and bill for medical services, without any vendor lock in. The Phyaura community

The study compared trastuzumab emtansine to standard treatment with Herceptin (trastuzumab) plus docetaxel chemotherapy. The results of the trial suggested that the patients who were given trastuzumab emtansine

The results of the trial also suggested that the combined theraphy also helps in the reduction of the risk of cancer progression by 57% versus exemestane alone in

The FDA approval is based on the results of different studies evaluating Remicade in adults with ulcerative colitis plus additional data from a Phase 3 trial investigating the

Faslodex is an oestrogen receptor antagonist, which can bind, block and degrade the oestrogen receptor, thereby helping in the treatment of hormone receptor-positive metastatic breast cancer which has

The study , which was conducted between 2004 and 2009, evaluated the efficiency of isolated soy protein consumption on the progression of atherosclerosis. The double-blind, placebo-controlled parallel-design study

Single-tablet regimen, Eviplera, combines Gilead’s Truvada (emtricitabine and tenofovir disoproxil (as fumarate)) with Tibotec Pharmaceuticals’ non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine (as hydrochloride)). The submission of the application